Evaluating the Efficacy and Value Proposition of Modern Diabetic Drugs- Insights for Brokers and Their Groups
As the pipeline of drugs for diabetes management continues to grow, benefit partners and advisors and the employer groups they serve are positioned to influence significant decisions that will impact healthcare spending. With some groups spending millions for diabetic drugs alone, it’s critical to understand the full spectrum of medications available, including newer players like […]
